DNA’s chemical cousin, RNA, was the messenger that carries DNA instructions from the double helix in the cell’s nucleus to ...

As aging progresses, the quality of DNA and proteins inside cells declines, which is known to be the cause of various ...

Company to Highlight the Role of Precision Diagnostics in Transforming Rare and Undiagnosed Disease CareHOUSTON, Aug. 25, ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration ...

The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

The cuts risk making the world a more dangerous place. To assess the impact of these measures, The Economist spoke to more ...